These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37309030)

  • 1. Cellular Immunobiology and Molecular Mechanisms in Alloimmunity-Pathways of Immunosuppression.
    Schrezenmeier E; Dörner T; Halleck F; Budde K
    Transplantation; 2024 Jan; 108(1):148-160. PubMed ID: 37309030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Immunosuppression Management: Opportunities and Uncertainties.
    Wojciechowski D; Wiseman A
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1264-1271. PubMed ID: 33853841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
    Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
    Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
    Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunosuppressive treatments: mechanisms of action and clinical use].
    Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
    Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
    Kamar N; Del Bello A; Belliere J; Rostaing L
    Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
    Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
    Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
    Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
    Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
    Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
    Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments.
    Giessing M; Fuller TF; Tuellmann M; Slowinski T; Budde K; Liefeldt L
    World J Urol; 2007 Jun; 25(3):325-32. PubMed ID: 17333201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM; Brown NW; Dhawan A
    Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.